Alefacept: all 32 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Alefacept and Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT01319851Not applicableResults posted
- Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host DiseaseTerminatedNCT01226420Phase 2Results posted
- Inducing Remission in Type 1 Diabetes With AlefaceptTerminatedNCT00965458Phase 2Results posted
- Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF TherapyTerminatedNCT00953329Phase 4Results posted
- Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic DermatitisCompletedNCT00832585Phase 4Results posted
- A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra PilarisTerminatedNCT00815633Phase 4Results posted
- Open Label Study of Alefacept Injections to Patients With Moderate to Severe PsoriasisCompletedNCT00678470Not applicableResults posted
- Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type PsoriasisCompletedNCT00655564Phase 4Results posted
- A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant RecipientsCompletedNCT00617604Phase 2Results posted
- A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant RecipientsCompletedNCT00543569Phase 2Results posted
- Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's LymphomaCompletedNCT00438802Phase 1Results posted
- Alefacept in Patients With Severe Scalp Alopecia AreataCompletedNCT00167102Not applicableResults posted
- Alefacept in Kidney Transplant RecipientsWithdrawnNCT01433770Not applicable
- Alefacept in Patients With Relapsed/Refractory Aplastic AnemiaTerminatedNCT01267643Phase 1
- A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant RecipientsTerminatedNCT01163799Phase 1
- Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe PsoriasisCompletedNCT00808223Phase 2
- Safety and Tolerability of Repeat Courses of IM AlefaceptCompletedNCT00794807Phase 4
- Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque PsoriasisCompletedNCT00692172Phase 3
- A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00674063Phase 3
- A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or InappropriateCompletedNCT00673556Phase 3
- A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic ArthritisCompletedNCT00659412Phase 2
- A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy VolunteersCompletedNCT00653822Phase 1
- Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque PsoriasisCompletedNCT00493324Phase 4
- Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan PatientsCompletedNCT00422617Not applicable
- Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.CompletedNCT00407342Not applicable
- Alefacept for Chronic Graft Versus Host DiseaseCompletedNCT00397332Phase 1/2
- Open-Label,Singel Center Study of Alefacept in Patients With Atopic DermatitisCompletedNCT00376129Phase 2
- Alefacept for Prevention of Graft Versus Host Disease (GVHD)TerminatedNCT00361413Phase 3
- Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar PustulosisCompletedNCT00301002Phase 2
- Safety and Tolerability of Repeat Courses of IM AlefaceptCompletedNCT00233662Phase 3
- Community Based Trial for AMEVIVE®CompletedNCT00168753Phase 4
- A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen PlanusTerminatedNCT00135733Phase 2